Zai Lab 2026 ESMO Investor Call - ZAI LAB LTD

Financial Performance:

• No specific revenue, earnings, margin, cash flow, or debt metrics were disclosed in this transcript as the call focused on clinical trial data rather than quarterly financial results.

Guidance and Future Outlook:

• Three registrational trials (second-line SCLC, second-line extrapulmonary NEC, first-line SCLC) are expected to be underway by the end of the year.
• First potential U.S. Biologics License Application (BLA) submission anticipated next year.
• Multiple important data readouts for key programs expected within the next 12 to 18 months.
• Global Phase III first-line extensive stage small cell lung cancer (ES-SCLC) study aims to initiate by the end of the year.

Business Segments and Product Lines:

• SOSi (Zoliflumab): A DLL-3-targeted antibody-drug conjugate (ADC) currently the lead oncology asset; demonstrating high response rates and durability in first-line SCLC (81.4% confirmed ORR in doublet, 92.3% in triplet).
• ZL-15L3: Long-acting IL-13/IL-31 receptor alpha agonist for immunology; first clinical data readout expected next month.
• Pipeline Expansion: Exploring SOSi in other DLL-3 expressing cancers including immediate stage SCLC, large cell neuroendocrine carcinoma, and brain tumors.
• Strategic Partnerships: Collaborating with partners (Vi and Amgen) to test SOSi combinations with T-cell engagers (TCEs) and immunotherapy as standard of care.

Market and Competitive Landscape:

• Current standard of care for first-line SCLC involves platinum-etoposide chemotherapy plus immunotherapy, but management aims to replace chemotherapy with an ADC backbone for superior efficacy and tolerability.
• SOSi compared favorably against standard chemoimmunotherapy (e.g., EMPOWER-133 data showing ~30% 6-month PFS vs. SOSi's 81.9%).
• Competition exists in the SCLC space, but SOSi's favorable safety profile and broad intracranial activity are positioned as key differentiators.

Risks and Challenges:

• Safety Trade-offs: The triplet regimen (SOSi + Atezolizumab + Carboplatin) showed higher toxicity, specifically hematological events (neutropenia, thrombocytopenia), compared to the doublet.
• Trial Complexity: Operational challenges in enrolling and executing global Phase III trials.
• Uncertainty: Long-term durability and intracranial activity in the first-line setting are currently inferred from second-line data and require further follow-up.
• Market Competition: Rapidly evolving landscape with emerging T-cell engagers (e.g., Tarlatamab) and other ADCs.

Management Commentary and Tone:

• Tone is highly confident and optimistic, citing the data as a "strong clinical rationale" to replace chemotherapy in the first-line setting.
• Management emphasizes SOSi's "best-in-class tolerability" as a critical driver for its potential to serve as a backbone for combination therapies.
• Focus on "continuous front-line treatment" to remove the attrition between induction and maintenance phases inherent in current standards.

Analyst Questions and Answers:

• Enrollment Timelines: Second-line study enrollment is proceeding well with data analysis and filing targeted for next year; first-line study aims to start by year-end with regulatory approval secured.
• Chemo Replacement: Consensus is to replace chemotherapy in the first line with SOSi-based regimens due to superior tolerability and efficacy; chemotherapy may be reserved for later lines.
• Differentiation Drivers: Key differentiation factors identified are durability, rapid onset of response, intracranial activity (effective in untreated brain metastases), and safety profile enabling combination use.
• Triplets vs. Doublets: Management plans to advance the doublet regimen in Phase III; triplets with chemotherapy may have a role in specific subgroups but the strategic preference leans toward chemo-free combinations.

Other Key Points:

• Clinical Data Highlights: 6-month progression-free survival (PFS) of 81.9% in the first-line doublet cohort; median duration of response not yet reached.
• Safety Profile: No dose-limiting toxicities observed in dose escalation; only 9.1% of patients on the doublet experienced grade 3+ adverse events related to SOSi; no treatment-related deaths reported.
• Intracranial Activity: High activity observed in patients with untreated brain metastases, addressing a critical unmet need where 80% of patients develop CNS disease.
• Mechanism of Action: SOSi features a cleavable linker enabling a strong bystander effect, releasing payload in the tumor microenvironment.